Clinical Trial Search

Primary: Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26 — 7.12; 7.76; 21.80 Percentage of patients — p=0.7871

Primary: Plasma Alkylresorcinol Compounds — 19357; 1548; 17307; 5385 nmol/L*h

Primary: Change in Reactive Hyperemia Index (RHI) From Baseline (20 Min Before Product Intake) to 2 Hours Following Product Intake — 2.12; 2.30; 2.26 percentage of the pulse wave…

Primary: Length of Hospital Stay — 4.6; 6.8 days

Primary: Post-prandial Plasma Responses of Glucose Concentrations — 136.5; 121.2; 102.9; 160.3 mmole/L*min

Primary: Cigarette Use — 12.6; 2.1 cigarettes/day

Primary: Number of Participants With Clinical Outcome of Post Transplant Lymphoproliferative Disease (PTLD) — 0; 0; 0; 0 participants

Primary: Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient…

Primary: Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19 — 97.37; 93.94; 100.00; 100.00 Percentage of participants…

Primary: Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot…

Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…

Primary: Number of Clinically Significant Bleeding Events — 116; 178 events — p=0.13

Primary: Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed — 72.4; 65.4 percentage of participants

Primary: Percentage of Participant Who Were Non-Failures — 52.2; 44.4; 13.0 percentage of participants — p=0.007

Primary: Change From Baseline in Visual Acuity (VA) at Final Visit — 0.61; 0.15 logMAR